Background
==========

Rheumatoid arthritis (RA) is a common immune-mediated chronic inflammatory disease \[[@B1]\]. Severe clinical symptoms of RA comprise bone lose \[[@B2]\] and heart diseases \[[@B3]\] that can make a huge destruction to human body. RA is a complex disease caused by both genetic and environmental factors. Twin studies estimated a large heritability (60%) in RA \[[@B4]\]. Family-based studies also demonstrated that genetic factors played a more important role in the development of RA than environmental factors \[[@B5],[@B6]\].

Consistent association was found between human leukocyte antigen (HLA) loci and RA \[[@B7]\]. The transporter associated with antigen processing 2 (*TAP2*) gene encodes transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) that is a major histocompatibility complex (MHC) gene located between HLA-DP and HLA-DQ \[[@B8]\]. TAP2 delivers antigenic peptides to the endoplasmic reticulum of HLA class I molecular \[[@B9]\], especially in selecting the size of peptides \[[@B10]\]. *TAP2* has been shown to play an important role in the HLA-associated diseases and immune response \[[@B11]\].

*TAP2* polymorphisms have been tested for their association with the occurrence and development of RA \[[@B12]-[@B23]\]. Among them, Ile379Val, Ala565Thr and Thr665Ala are most often studied \[[@B14]-[@B23]\]. Altogether there were 10 case--control studies for the *TAP2* polymorphisms with RA, yielding only 2 significant results (Table [1](#T1){ref-type="table"}). We suspected that a lack of power in the previous studies with moderate sample size might influence the reliability of the results \[[@B24]\]. Meta-analysis is often used to enhance statistical power and thus is likely to produce a more convincing conclusion \[[@B25]\]. Here we performed a set of meta-analyses of the three polymorphisms by pooling up the data from individual association study \[[@B25]\]. Our research is likely to provide a better evaluation of the contribution of *TAP2* polymorphisms to the risk of RA.

###### 

Characteristics of the case--control studies in the current meta-analyses

  **Gene locus**   **First author**               **Year**   **Country**   **Ethnicity**   **Genotyping method**   **Cases/controls**   **Control source**   **HWE**   **Result\***   **Power**   **MAF**
  ---------------- ------------------------------ ---------- ------------- --------------- ----------------------- -------------------- -------------------- --------- -------------- ----------- ---------
  *TAP2*-379       B. P. Wordsworth \[[@B14]\]    1993       Britain       Europeans       ARMS-PCR                60/117               Population           NA        NS             0.101       0.167
                   Sara Marsal \[[@B15]\]         1994       America       Europeans       ARMS-PCR                185/48               Population           NA        NS             0.086       0.177
                   M.C. Hillarby \[[@B16]\]       1996       Britain       Europeans       ARMS-PCR                89/64                Population           NA        S              0.091       0.172
                   F. Takeuchi \[[@B17]\]         1997       Japan         Asians          PCR-RFLP                92/95                Population           NA        NS             0.095       0.132
                   J Vinasco \[[@B18]\]           1998       Spain         Europeans       PCR-RFLP                50/55                Population           NA        NS             0.072       0.109
                   Sasijit Vejbaesya \[[@B19]\]   2000       Thailand      Asians          ARMS-PCR                82/100               Population           Yes       NS             0.115       0.220
                   S.-L. Zhang \[[@B20]\]         2002       France        Europeans       ARMS-PCR                138/100              Population           Yes       NS             0.098       0.120
                   Min-Chien Yu \[[@B21]\]        2004       China         Asians          PCR-RFLP                100/99               Population           Yes       NS             0.124       0.237
  *TAP2*-565       B. P. Wordsworth \[[@B14]\]    1993       Britain       Europeans       ARMS-PCR                60/117               Population           NA        NS             0.094       0.132
                   Sara Marsal \[[@B15]\]         1994       America       Europeans       ARMS-PCR                185/48               Population           NA        NS             0.081       0.156
                   M.C. Hillarby \[[@B16]\]       1996       Britain       Europeans       ARMS-PCR                89/64                Population           NA        NS             0.086       0.148
                   F. Takeuchi \[[@B17]\]         1997       Japan         Asians          PCR-RFLP                92/95                Population           NA        S              0.09        0.116
                   J Vinasco \[[@B18]\]           1998       Spain         Europeans       PCR-RFLP                50/55                Population           NA        NS             0.059       0.036
                   S.-L. Zhang \[[@B20]\]         2002       France        Europeans       ARMS-PCR                138/100              Population           Yes       S              0.078       0.070
                   Min-Chien Yu \[[@B21]\]        2004       China         Asians          PCR-RFLP                100/99               Population           Yes       NS             0.086       0.096
                   Yu L \[[@B22]\]                2013       China         Asians          PCR-RFLP                177/288              Population           Yes       NS             0.169       0.142
  *TAP2*-665       B. P. Wordsworth \[[@B14]\]    1993       Britain       Europeans       ARMS-PCR                60/117               Population           NA        NS             0.115       0.248
                   Sara Marsal \[[@B15]\]         1994       America       Europeans       ARMS-PCR                185/48               Population           NA        NS             0.084       0.167
                   M.C. Hillarby \[[@B16]\]       1996       Britain       Europeans       ARMS-PCR                89/64                Population           NA        NS             0.119       0.375
                   F. Takeuchi \[[@B17]\]         1997       Japan         Asians          PCR-RFLP                92/95                Population           NA        NS             0.136       0.347
                   J Vinasco \[[@B18]\]           1998       Spain         Europeans       PCR-RFLP                50/55                Population           NA        NS             0.091       0.264
                   Juha Tuokko \[[@B23]\]         1998       Finland       Europeans       PCR-RFLP                40/60                Population           No        NS             0.095       0.350
                   S.-L. Zhang \[[@B20]\]         2002       France        European        ARMS-PCR                138/100              Population           Yes       NS             0.148       0.300
                   Min-Chien Yu \[[@B21]\]        2004       China         Asians          PCR-RFLP                100/99               Population           Yes       NS             0.147       0.601\*

ARMS-PCR: Amplification refractory mutation system; PCR-RFLP: Polymerase Chain Reaction --Restriction Fragment Length Polymorphism; HWE.

Hardy-Weinberg equilibrium; Result\*, The association between IL1B gene and PD; NS, No significant; S, Significant; NA: Not applicable; \*The reference allele is TAP2-665Ala.

Methods
=======

We collected studies that examined the associations of *TAP2* polymorphisms with RA in September of 2013 by searching the online databases (PubMed, WanFang, WeiPu and CNKI) without time and language restriction, using the keywords "rheumatoid arthritis *TAP2* association" and "rheumatoid arthritis *TAP2* polymorphism". The obtained studies would be included in our meta-analyses if they met the following criteria: (1) It was an original case--control study with an assessment of the association of *TAP2* with RA in humans; (2) It contains sufficient information to infer the odds ratios (ORs) and 95% confidence intervals (95% CIs); (3) Genotype distribution of each polymorphism in controls met Hardy-Weinberg equilibrium (HWE); (4) The cumulative number of individual studies for one genetic locus are at least three. We extracted or calculated the following information from each selected study: the first author, year of publication, country, ethnicity, genotyping method, numbers of cases and controls, control source, HWE for controls, reported association results, power of each involved study and minor allele frequency (MAF) in each stage.

Since some studies presented the data of haplotypes (A to H, Table [2](#T2){ref-type="table"}), our study translated the haplotypes into the genotypes of three coding polymorphisms (*TAP2*-379, *TAP2*-565, and *TAP2*-665) \[[@B8],[@B26]\]. We used Arlequin program \[[@B27]\] to test whether the genotyping distribution in controls was in HWE. Cochran's Q statistic and I^2^ test \[[@B28]\] were used to calculate statistical heterogeneity. Fixed-effect model would be used to the studies with minimal to moderate heterogeneity (I^2^ \< 50%), and the random-effect model would be used to the studies with significant heterogeneity (I^2^ \> =50%). Combined ORs and CIs were estimated by Review Manager 5 \[[@B29]\]. Funnel plots were drawn to observe the potential publication bias. The power of each study was calculated by Power and Sample Size Calculation program. All the statistical analyses were performed by two independent reviewers (Ping Ru and Xingyu Zhou).

###### 

Nomenclature of TAP2 haplotypes

   **TAP2**   **TAP2-379**   **TAP2-565**   **TAP2-665**              
  ---------- -------------- -------------- -------------- ----- ----- -----
      A           Val                           Ala              Thr     
      B           Val                           Ala                    Ala
      C                          Ile            Ala              Thr     
      D                          Ile                       Thr   Thr     
      E           Val                                      Thr   Thr     
      F           Val                           Ala              Thr     
      G                          Ile            Ala                    Ala
      H                          Ile                       Thr         Ala

Val: Valine; Ile: Isoleucine; Ala: Alanine; Thr: Threonine.

Results and discussion
======================

As shown in Figure [1](#F1){ref-type="fig"}, 22 genetic studies on *TAP2* gene were initially collected. Of them, we excluded 7 studies that were not related to RA, 1 case-only study, 4 studies without genotyping information, 1 study that did not meet HWE. Finally, 9 articles \[[@B14]-[@B22]\] were involved in the current study. Altogether, there were 973 RA patients and 965 controls in the meta-analyses of 3 *TAP2* polymorphisms (Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}).

![Flowchart of selection process in the meta-analyses.](1746-1596-9-129-1){#F1}

###### 

Meta-analyses of TAP2-379, TAP2-565, TAP2-665with RA\*

  **Genetic locus**   **Cases/controls (S\*)**   **Genetic model**           **Ethnicity**   **OR (95% CI)**     ***P*value**   **I**^**2**^   **Power**
  ------------------- -------------------------- --------------------------- --------------- ------------------- -------------- -------------- -----------
  *TAP2*-379          796/677 (8)                Overall ( I vs V)           Overall         1.44 (1.18-1.74)    0.0002         42%            0.477
                      522/768 (5)                                            Europeans       1.39 (0.88-2.20)    0.16           64%            0.286
                      274/293 (3)                                            Asians          1.38 (1.04-1.83)    0.03           0%             0.241
                      320/298 (3)                Dominant ( II/IV vs VV )                    1.59 (1.14-2.22)    0.006          0%             0.336
                      320/298 (3)                Recessive ( II vs IV/VV )                   1.24 (0.58-2.64)    0.58           0%             0.104
                      198/209 (3)                Additive ( II vs VV )                       1.49 (0.68-3.23)    0.32           0%             0.101
  *TAP2*-565          891/871 (8)                Overall ( T vs A )          Overall         1.23 (0.84-1.81)    0.28           64%            0.439
                      522/778 (5)                                            Europeans       1.62 (1.20-2.20)    0.002          24%            0.229
                      369/482 (3)                                            Asians          0.87 (0.43-1.75)    0.70           76%            0.254
                      415/487 (3)                Dominant ( TT/TA vs AA )                    1.17 (0.85-1.61)    0.33           45%            0.379
                      415/487 (3)                Recessive ( TT vs TA/AA )                   4.71 (0.51-43.33)   0.17           64%            0.075
                      335/384 (3)                Additive ( TT vs AA )                       4.64 (0.52-41.77)   0.17           64%            0.075
  *TAP2*-665          714/578 (7)                Overall ( A vs T )          Overall         1.02 (0.85-1.22)    0.84           48%            0.557
                      522/384 (5)                                            Europeans       0.87 (0.69-1.09)    0.23           39%            0.475
                      192/194 (2)                                            Asians          1.32 (0.99-1.77)    0.06           0%             0.080
                      238/199 (2)                Dominant ( AA/AT vs TT )                    1.07 (0.44-2.57)    0.88           67%            0.252
                      238/199 (2)                Recessive ( AA vs AT/TT )                   0.58 (0.06-5.77)    0.64           77%            0.131
                      128/100 (2)                Additive ( AA vs TT )                       1.15 (0.53-2.49)    0.73           83%            0.122

S\*: Amount of stages; V: Valine; I: Isoleucine; A: Alanine; T: Threonine.

In the present study, we tested the associations between 3 *TAP2* polymorphisms and RA disease. Different inheritable models, including dominant, recessive and additive models, were also tested for all 3 polymorphisms. As shown in Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, a significant association of *TAP2*-379Ile with increased risk of RA was found for combined population (*p* = 0.0002, OR = 1.40, 95% CI = 1.16-1.70). Subgroup analysis by ethnicity showed that this significant association was only found in Asians (*p* = 0.03, OR = 1.38, 95% CI = 1.04-1.83, Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}) but not in Europeans (*p* = 0.16, Table [3](#T3){ref-type="table"}). In addition, significant contribution of *TAP2*-379Ile to RA was only found in the dominant model (*p* = 0.006, OR = 1.59, 95% CI = 1.14-2.22, Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). For *TAP2*-565Thr, there was no significant result in the combined populations (*p* = 0.28, Table [3](#T3){ref-type="table"}), but we found significant association between Europeans and RA (*p* = 0.002, OR = 1.62, 95% CI = 1.20-2.20, Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). For *TAP2*-665 locus, no significant result was found in the combined meta-analyses or in the subgroup meta-analyses (Table [3](#T3){ref-type="table"}).

![**Forest plots of TAP2 gene polymorphisms with RA. A**: Forest plot of *TAP*-379 with RA for combined population; **B**: Forest plot of *TAP*-379 with RA in Asians; **C**: Forest plot of *TAP*-379 with RA under dominant effect model; **D**: Forest plot of *TAP*-565 with RA in Europeans.](1746-1596-9-129-2){#F2}

Significant statistical heterogeneity was found in the meta-analyses of *TAP2*-565 (I^2^ = 64%). A further subgroup meta-analyses by ethnicity showed that significant heterogeneity was coming from the Europeans for *TAP2*-379 (I^2^ = 64%) and Asians for *TAP2*-565 (I^2^ = 76%). Further subgroup studies showed that significant heterogeneity also existed in the meta-analyses of *TAP2*-565 (recessive model: I^2^ = 64%; additive model: I^2^ = 64%) and *TAP2*-665 (dominant model: I^2^ = 67%, recessive model: I^2^ = 77%; additive model: I^2^ = 83%).

All the power analyses in current meta-analyses were tested under a moderate risk of SCZ (OR = 1.2, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Compared with previous individual studies, our meta-analyses showed a much stronger power (Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}). In addition, no publication bias for the meta-analyses was observed (Figure [3](#F3){ref-type="fig"}).

![Funnel plots of TAP2 gene polymorphisms with RA.](1746-1596-9-129-3){#F3}

To our knowledge, our study was the first meta-analyses of the three coding polymorphisms of *TAP2* gene. Previous studies showed significant association between *TAP2* gene and autoimmune diseases such as allergic rhinitis \[[@B30]\], systemic lupus erythematosus \[[@B31]\] and RA \[[@B20],[@B21]\]. Our results indicated that *TAP2*-379Ile was able to increase 44% of the risk of RA in all subjects and 38% of the risk of RA in Asians. Moreover, *TAP2*-379Ile was associated with a 59% increased risk of RA in the dominant model. We also found that *TAP2*-565Thr increased the risk of RA by 62% in Europeans.

Previous RA association studies observed a handful of single nucleotide polymorphisms (SNPs) with dominant effect such as -607A/C polymorphism of *IL-18* gene \[[@B32]\], rs10489629 of *IL-23R* gene \[[@B33]\], -173G/C polymorphism of *MIF* gene \[[@B34]\] and -607A/C polymorphism of *IL-18* gene \[[@B32]\]. Our observation of significant association of *TAP2*-379Ile polymorphism in the dominant model supported that dominant model might be a key genetic model in the pathogenesis of RA disease.

Since MAFs are different in different populations, we further evaluated the role of *TAP2* polymorphisms in Asians and Europeans separately. For *TAP2*-379Ile, significant association was found in Asians but not in Europeans. On the contrary, we observed *TAP2*-565Thr as a risky factor of RA in Europeans but not in Asians. This might be due to a lack of power in the subgroup meta-analysis in Europeans for *TAP2*-379 (power = 0.286, I^2^ = 64%) and in Asians for *TAP2*-565 (power = 0.254, I^2^ = 76%). To be noted, one Asian study \[[@B21]\] involved in the meta-analyses of *TAP2*-665Ala was found a high allele frequency (allele frequency = 0.601, Table [1](#T1){ref-type="table"}) than those in the rest studies (average allele frequency = 0.284).

Our meta-analyses presented several limitations that needed to be taken with cautions. Firstly, the associations of *TAP2* polymorphisms were only evaluated in Europeans and Asians. The findings might not be feasible for other populations such as Africans. And potential difference in intra-European and intra-Asian population might influence the result of our study (see the MAFs in Table [1](#T1){ref-type="table"}). Secondly, RA is a complex chronic disease. Different clinical variables may influence the results of the current study. Hidden physiological factors may exist in the RA patients and affect the quality of the current meta-analysis. Further studies with precise diagnosis might be helpful for a better meta-analysis in the future. Thirdly, although the power of current meta-analyses was much stronger than the previous studies, more replicated studies are required to strengthen the stability of the association between *TAP2* polymorphisms and RA. Fourthly, certain multiple testing existed in the current study, and cautions needed to be taken for the significant results. Fifthly, there are 2232 polymorphisms in *TAP2* gene according to the NCBI dbSNP database. Our study only focused on three polymorphisms of *TAP2* that might be hard to give fully consideration of the contribution of *TAP2* polymorphisms. Moreover, the 3 *TAP2* polymorphisms might not be the causal variants but be in high linkage disequilibrium with other established RA MHC variants. Sixthly, since significant associations were found in the both allelic and dominant model for *TAP2*-379, our results implied the genetic models of *TAP2*-379 polymorphism were complex and hard to be determined. Seventhly, there were publication biases for the current meta-analyses of *TAP2*-379 and *TAP2*-565. After removing the outlier studies \[[@B16],[@B17]\], the results of the two meta-analyes remained the same as the previous one.

Conclusions
===========

In summary, our meta-analyses suggested that *TAP2*-379Ile allele was significantly associated with a 59% increased risk in the dominant model. To be more specifically, *TAP2*-379-Ile increased the risk of RA by 38% in Asians and *TAP2*-565Thr increased the risk of RA by 38% in Europeans. Future large-scale and well designed studies are required to confirm our findings and to reveal other *TAP2* polymorphisms with contribution to RA disease.
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